Eli Lilly Lowers Cash Price for Weight-Loss Drug Zepbound
Eli Lilly has implemented price reductions for cash purchasers of its weight-loss medication, Zepbound. This move reflects strategic adjustments in response to market conditions affecting drug pricing and patient access to medication. The price reduction could influence payer coverage decisions and out-of-pocket costs for consumers paying without insurance support.